Gene expression of the invasive phenotype of TNF-α-treated MCF-7 cells

Biomedicine and Pharmacotherapy

Volumn 63, Issue 6, 2009, Pages 421-428

  Yin, Yongmei ^a   Chen, Xiaofeng ^a   Shu, Yongqian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cDNA array; MCF 7 cells; TNF

Indexed keywords

APC PROTEIN; BETA3 INTEGRIN; CD146 ANTIGEN; CD61 ANTIGEN; CHEMOKINE; COLLAGENASE 3; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPHRIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBRONECTIN; GELATINASE A; GELATINASE B; GONADORELIN; HERMES ANTIGEN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 8 RECEPTOR; MATRILYSIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR; PROTEIN MDM2; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68649128083     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.032     Document Type: Article

References (48)

1. Anderson G.M., Nakada M.T., and DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4 (2004) 314-320
2. Zarovni N., Monaco L., and Corti A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 15 4 (2004) 373-382
3. Mochizuki Y., Nakanishi H., Kodera Y., Ito S., Yamamura Y., Kato T., et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 21 1 (2004) 39-47
4. Hecht JR, Hanna N, Chung T, Vogel S, Rosemurgy A, Nemuniatis J, et al. Preliminary results of a dose escalation trial of TNF erade in combination with 5-fluorouracil(5-FU) and radiation in locally advanced pancreatic cancer. In: Fifth Annual Meeting of the American Association for Cancer Research. Orlando, FL; 27-31 March 2004 [abstract number 2344].
5. Mantovani G., Maccio A., Mura L., Massa E., Mudu M.C., Mulas C., et al. Serum level of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78 (2000) 554-561
6. Karayiannakis A.J., Syigos K.N., Ploychronidis A., Pitiakoudis M., Bounovas A., and Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21 (2001) 1355-1358
7. Yoshida N., Ikemoto S., Narita K., Sugimura K., Wada S., Yasumoto R., et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 86 9 (2002) 1396-1400
8. Leek R.D., Landers R., Fox S.B., Ng F., Harris A.L., and Levis C.E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77 12 (1998) 2246-2251
9. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace Jr. D., and Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 (2003) 1211-1216
10. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4 (2003) 565-573
11. Szlosarek P., Charles K.A., and Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42 (2006) 745-750
12. Schwamborn J., Lindecke A., Elvers M., Horejschi V., Kerick M., Rafigh M., et al. Microarray analysis of tumor necrosis factor alpha induced gene expression in U373 human glioblastoma cells. BMC Genomics 4 (2003) 46
13. Roepman P., Wessels L.F., Kettelarij N., Kemmeren P., Miles A.J., Lijnzaad P., et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37 (2005) 182-186
14. Bidus M.A., Risinger J.I., Chandramouli G.V., Dainty L.A., Litzi T.J., Berchuck A., et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res 12 (2006) 83-88
15. Lyng H., Brøvig R.S., Svendsrud D.H., Holm R., Kaalhus O., Knutstad K., et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 20 (2006) 268
16. Smid M., Wang Y., Klijn J.G., Sieuwerts A.M., Zhang Y., Atkins D., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24 (2006) 2261-2267
17. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
18. Hao X., Sun B., Hu L., Lähdesmäki H., Dunmire V., Feng Y., et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100 (2004) 1110-1122
19. Seeger H., Wallwiener D., and Mueck A.O. Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci 78 (2006) 1464-1468
20. Nguyen D.H.D., Hussaini I.M., and Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273 14 (1998) 8502-8507
21. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135-1149
22. Yoon S.O., Park S.J., Yun C.H., and Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 36 1 (2003) 128-137
23. Wielockx B., Lannoy K., Shapiro S.D., Itoh T., Itohara S., Vandekerckhove J., et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 7 (2001) 1202-1208
24. Parks W.C., and Mecham R.P. Matrix metalloproteinases (1998), Academic Press, London
25. Mon N.N., Hasegawa H., Thant A.A., Huang P., Tanimura Y., Senga T., et al. A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. Cancer Res 66 (2006) 6778-6784
26. Johnsen M., Lund L.R., Romer J., Almholt K., and Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10 (1998) 667-671
27. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., and Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56 (1996) 190-196
28. Hagemann T., Robinson S.C., Schulz M., Trümper L., Balkwill F.R., and Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25 (2004) 1543-1549
29. Naor D., Sionov R.V., and Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 71 (1997) 241-319
30. Watanabe O., Kinoshita J., Shimizu T., Imamura H., Hirano A., Okabe T., et al. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 24 (2005) 75-82
31. Ryś J., Kruczak A., Lackowska B., Jaszcz-Gruchała A., Brandys A., Stelmach A., et al. The role of CD44v3 expression in female breast carcinomas. Pol J Pathol 54 (2003) 243-247
32. Harrell J.C., Dye W.W., Allred D.C., Jedlicka P., Spoelstra N.S., Sartorius C.A., et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66 (2006) 9308-9315
33. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
34. Lee B.C., Lee T.H., Avraham S., and Avraham H.K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2 (2004) 327-338
35. Kato M., Kitayama J., Kazama S., and Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5 5 (2003) R144-R150
36. Helbig G., Christopherson II K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278 24 (2003) 21631-21638
37. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 6 (2003) 537-549
38. Chen Y., Stamatoyannopoulos G., and Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 63 (2003) 4801-4804
39. Lee J.H., and Welch D.R. Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display. Int J Cancer 71 (1997) 1035-1044
40. Masui T., Doi R., Mori T., Toyoda E., Koizumi M., Kami K., et al. Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 315 1 (2004) 85-92
41. Lee J.H., and Welch D.R. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57 (1997) 2384-2387
42. Sanchez-Carbayo M., Capodieci P., and Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 162 (2003) 609-617
43. Ringel M.D., Hardy E., Bernet V.J., Burch H.B., Schuppert F., Burman K.D., et al. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab 87 5 (2002) 2399
44. Mitchell D.C., Abdelrahim M., Weng J., Stafford L.J., Safe S., Bar-Eli M., et al. Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J Biol Chem 281 (2006) 51-58
45. Stark A.M., Tongers K., Maass N., Mehdorn H.M., and Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131 (2005) 191-198
46. Yan C., Wang H., and Boyd D.D. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of I kappa B alpha-induced block of p65/p50 nuclear translocation. J Biol Chem 276 (2001) 1164-1172
47. Burke D., Wilkes D., Blundell T.L., and Malcolm S. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 23 2 (1998) 59-62
48. 388 Allele. Clin Cancer Res 10 18 Pt 1 (2004) 6169-6178